Moderna's Spikevax vaccine is the first to receive full approval for use in children aged 6 months to 11 years with a high-risk health issue.

While people living in the lowest-income census tract quartile (Q1) lost more life expectancy than the highest-income group ...

In just 3 years, the Influenza Vaccines Research and Development (R&D) Roadmap Initiative has demonstrated important ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...